Search our consultants’ directory

Prof Hashim U. Ahmed qualified from the University of Oxford where he attended St Peter’s College and Linacre College. Whilst he was a student he was awarded the William Osler Prize in Medicine. He then held house office posts in Queen Elizabeth Hospital, Birmingham and University Hospital Manchester before returning to Oxford for an anatomy prosector post.

Prof Ahmed then held senior house jobs in surgery on the Royal Free Hospital London rotation followed by specialist registrar posts at West Middlesex Hospital, Charing Cross Hospital and Imperial College London, University College Hospital and Watford General Hospital as part of the Imperial College urology rotation.

He was a Pelican Cancer Foundation research fellow, followed by a Medical Research Council (MRC) clinician research training fellowship at University College London at which time a number of imaging and focal therapy trials began. His research interests are in health technology evaluation including multi-parametric magnetic resonance imaging (MRI), histoscanning, tissue type imaging, as well as therapeutic interventions such as high intensity focused ultrasound, irreversible electroporation, photodynamic therapy, cryotherapy and radiofrequency ablation.

He has completed numerous phase I/II clinical trials evaluating the role of focal therapy in prostate cancer and is lead principal investigator and co-principal investigator in a number of multicentre trials including the UK National Institute for Health Research-Health Technology Assessment (NIHR-HTA) funded National Cancer Research Network (NCRN) PROMIS study evaluating the role of multi-parametric MRI in men with a raised PSA using template prostate mapping as the reference standard. Also for NCRN INDEX, a multicentre focal therapy study using high intensity focused ultrasound (HIFU) with three-year follow-up and NCRN FORECAST. He previously held a £1.2 million MRC Clinician Scientist Fellowship for five years and currently holds a £2 million Senior Clinical Research Fellowship from the Wellcome Trust.

He has been visiting professor to University of California, Los Angeles as well as Tokyo, Weill-Cornell and Detroit universities and has given over 30 plenary lectures at national and international urology, oncology and imaging meetings. The team he led recently was awarded the BMJ/BMA Innovation Award 2015 and the Health Services Journal Acute Sector Innovation Award 2016.

Mr David Hrouda qualified at St. Thomas’s Hospital Medical School in 1989 and carried out postgraduate surgical training in London at St George’s Hospital, the Institute of Urology (University College Hospital) and Charing Cross Hospital. He was awarded an MD thesis (2000) for research into prostate cancer vaccines and gene therapy.

He then undertook further training in laparoscopic urological surgery at Princess Alexandra Hospital in Brisbane and subsequently learned additional techniques while doing a preceptorship at The Cleveland Clinic, Cleveland, Ohio. He has been a consultant urological surgeon at Imperial College Healthcare NHS Trust (Charing Cross Hospital) and West Middlesex University Hospital since 2002.

He has a special interest in the diagnosis and treatment of testis, kidney and bladder cancer with specialist skills in laparoscopic surgery, cystectomy and bladder reconstruction. He has performed over 1000 laparoscopic kidney operations.He performs post-chemotherapy retroperitoneal lymph node dissection for the North West London and Mount Vernon cancer networks.

In 2012-2014 he was a member of the National Cancer Research Institute (NCRI) clinical studies group for bladder cancer and a member of the screening, prevention & early diagnosis advisory group (SPED) of the NCRI. He is also a member of the senate of the clinical reference group for specialist urology, NHS England.

He is the clinical director for specialist surgery at Imperial College Healthcare NHS Trust and joint chair of the urology pathway group of the Royal Marsden cancer vanguard.